Liver Disease in the HIV-Infected Individual

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 12, 2010, Pages 1002-1012

  Price, Jennifer C ^a   Thio, Chloe L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatitis B Virus; Hepatitis C Virus; Human Immunodeficiency Virus; Liver Disease

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; MARAVIROC; NEVIRAPINE; RITONAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ACALCULOUS CHOLECYSTITIS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACQUIRED IMMUNE DEFICIENCY SYNDROME CHOLANGIOPATHY; ALCOHOL ABUSE; ALCOHOL LIVER DISEASE; BILE DUCT DISEASE; DRUG HYPERSENSITIVITY; DRUG TOXICITY; FATTY LIVER; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERSENSITIVITY REACTION; LIVER DISEASE; LIVER HYPERPLASIA; LIVER TOXICITY; MITOCHONDRIAL TOXICITY; NEOPLASM; NONALCOHOLIC FATTY LIVER; OPPORTUNISTIC INFECTION; REVIEW; SIDE EFFECT; VIRUS REACTIVATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG-INDUCED LIVER INJURY; FATTY LIVER; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER DISEASES; LIVER DISEASES, ALCOHOLIC;

EID: 78649718814     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2010.08.024     Document Type: Review

References (99)

1. Schneider M.F., Gange S.J., Williams C.M., et al. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS 2005, 19:2009-2018.
2. Palella F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
3. Palella F.J., Baker R.K., Moorman A.C., et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006, 43:27-34.
4. Smith C. Group TDCoAEoA-HIVdS: factors associated with specific causes of death amongst HIV-positive individuals in the D: A: D study. AIDS 2010, 24:1537-1548. Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group.
5. Bica I., McGovern B., Dhar R., et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001, 32:492-497.
6. Martin-Carbonero L., Soriano V., Valencia E., et al. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retrovir 2001, 17:1467-1471.
7. Pol S., Lebray P., Vallet-Pichard A. HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis 2004, 38(Suppl 2):S65-S72.
8. Cappell M.S. Hepatobiliary manifestations of the acquired immune deficiency syndrome. Am J Gastroenterol 1991, 86:1-15.
9. Lefkowitch J.H. Pathology of AIDS-related liver disease. Dig Dis 1994, 12:321-330.
10. Sulkowski M.S. Management of hepatic complications in HIV-infected persons. J Infect Dis 2008, 197(Suppl 3):S279-S293.
11. Crum-Cianflone N., Collins G., Medina S., et al. Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons. Clin Gastroenterol Hepatol 2010, 8:183-191.
12. Weber R., Sabin C.A., Friis-Moller N., et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study. Arch Intern Med 2006, 166:1632-1641.
13. Sulkowski M.S. Viral hepatitis and HIV coinfection. J Hepatol 2008, 48:353-367.
14. Staples C.T., Rimland D., Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V. A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999, 29:150-154.
15. Thomas D.L., Astemborski J., Rai R.M., et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000, 284:450-456.
16. Telfer P., Sabin C., Devereux H., et al. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994, 87:555-561.
17. Soto B., Sanchez-Quijano A., Rodrigo L., et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997, 26:1-5.
18. Benhamou Y., Bochet M., Di Martino V., et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients: the Multivirc Group. Hepatology 1999, 30:1054-1058.
19. Graham C.S., Baden L.R., Yu E., et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001, 33:562-569.
20. Berenguer J, Crespo M, Galindo M, et al. Sustained virological response to interferon plus ribavirin reduces HIV progression and non-liver-related mortality in patients co-infected with HIV and HCV (abstract 167). Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections, February 16-19, 2010, San Francisco, California.
21. Thio C.L., Nolt K.R., Astemborski J., et al. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 2000, 38:575-577.
22. van de Laar T.J., Matthews G.V., Prins M., et al. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS 2010, 24:1799-1812.
23. Shaheen A.A., Myers R.P. Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection. HIV Clin Trials 2008, 9:43-51.
24. Vergara S., Macias J., Rivero A., et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007, 45:969-974.
25. Ghany M.G., Strader D.B., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
26. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
27. Vogel M., Dominguez S., Bhagani S., et al. Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort. Antivir Ther 2010, 15:267-279.
28. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438-450.
29. Carrat F., Bani-Sadr F., Pol S., et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004, 292:2839-2848.
30. Chung R.T., Andersen J., Volberding P., et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451-459.
31. Laguno M., Murillas J., Blanco J.L., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004, 18:F27-F36.
32. Soriano V. Treatment of chronic hepatitis C in HIV-positive individuals: selection of candidates. J Hepatol 2006, 44(Suppl):S44-S48.
33. McGovern B.H., Ditelberg J.S., Taylor L.E., et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006, 43:365-372.
34. Vispo E., Barreiro P., Pineda J.A., et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008, 13:429-437.
35. Mira J.A., Gutierrez-Valencia A., Gil I.L., et al. Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. Clin Infect Dis 2009, 49:e84-e91.
36. Bani-Sadr F., Denoeud L., Morand P., et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?. J Acquir Immune Defic Syndr 2007, 45:123-125.
37. Amorosa V.K., Slim J., Mounzer K., et al. The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. Antivir Ther 2010, 15:91-99.
38. Laufer N., Laguno M., Perez I., et al. Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther 2008, 13:953-957.
39. Kramer J.R., Giordano T.P., El-Serag H.B. Effect of human immunodeficiency virus and antiretrovirals on outcomes of hepatitis C: a systematic review from an epidemiologic perspective. Clin Gastroenterol Hepatol 2007, 5:1321-1328.
40. Brau N., Salvatore M., Rios-Bedoya C.F., et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006, 44:47-55.
41. Qurishi N., Kreuzberg C., Luchters G., et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003, 362:1708-1713.
42. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
43. Salmon-Ceron D., Rosenthal E., Lewden C., et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalite 2005 study. J Hepatol 2009, 50:736-745.
44. Puoti M., Airoldi M., Bruno R., et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev 2002, 4:27-35.
45. Hadler S.C., Judson F.N., O'Malley P.M., et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991, 163:454-459.
46. Bodsworth N.J., Cooper D.A., Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991, 163:1138-1140.
47. Thio C.L. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009, 49(Suppl):S138-S145.
48. Colin J.F., Cazals-Hatem D., Loriot M.A., et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999, 29:1306-1310.
49. Thio C.L., Seaberg E.C., Skolasky R., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360:1921-1926.
50. Kim H.N., Harrington R.D., Van Rompaey S.E., et al. Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. Int J STD AIDS 2008, 19:600-604.
51. Gandhi R.T., Wurcel A., Lee H., et al. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis 2003, 36:1602-1605.
52. Shire N.J., Rouster S.D., Stanford S.D., et al. The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2007, 44:309-314.
53. Clark S.J., Creighton S., Horner M., et al. Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression. Int J STD AIDS 2006, 17:67-69.
54. Keeffe E.B., Dieterich D.T., Han S.H., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008, 6:1315-1341. quiz 1286.
55. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents, 1-161, Accessed December 4, 2009. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
56. Milazzo L., Caramma I., Lai A., et al. Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy. Antivir Ther 2009, 14:869-872.
57. Reisler R.B., Han C., Burman W.J., et al. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr 2003, 34:379-386.
58. McGovern B. Hepatic safety and HAART. J Int Association Physicians AIDS Care 2004, 3(Suppl 2):S24-S40.
59. Sulkowski M.S., Thomas D.L., Chaisson R.E., et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000, 283:74-80.
60. Puoti M., Nasta P., Gatti F., et al. HIV-related liver disease: ARV drugs, coinfection, and other risk factors. J Int Association Physicians AIDS Care 2009, 8:30-42.
61. Soriano V., Puoti M., Garcia-Gasco P., et al. Antiretroviral drugs and liver injury. AIDS 2008, 22:1-13.
62. Drake A., Mijch A., Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis 2004, 39:129-132.
63. Zylberberg H., Pialoux G., Carnot F., et al. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis 1998, 27:1255-1258.
64. Hoffmann C.J., Charalambous S., Thio C.L., et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007, 21:1301-1308.
65. Sulkowski M.S., Mehta S.H., Chaisson R.E., et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004, 18:2277-2284.
66. Torti C., Lapadula G., Antinori A., et al. Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER cohorts. Infection 2009, 37:244-249.
67. Maida I., Nunez M., Rios M.J., et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006, 42:177-182.
68. Kovari H., Ledergerber B., Peter U., et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009, 49:626-635.
69. Galvan F.H., Bing E.G., Fleishman J.A., et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study. J Stud Alcohol 2002, 63:179-186.
70. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C: the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349:825-832.
71. Cooper C.L., Cameron D.W. Effect of alcohol use and highly active antiretroviral therapy on plasma levels of hepatitis C virus (HCV) in patients coinfected with HIV and HCV. Clin Infect Dis 2005, 41(Suppl 1):S105-S109.
72. Chaudhry A.A., Sulkowski M.S., Chander G., et al. Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort. HIV Med 2009, 10:133-142.
73. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43(Suppl 1):S99-S112.
74. Sulkowski M.S., Mehta S.H., Torbenson M., et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005, 19:585-592.
75. Crum-Cianflone N., Dilay A., Collins G., et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009, 50:464-473.
76. Grinspoon S., Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352:48-62.
77. Ogedegbe A.E., Thomas D.L., Diehl A.M. Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis 2003, 3:329-337.
78. Grunfeld C., Pang M., Doerrler W., et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74:1045-1052.
79. Lemoine M., Barbu V., Girard P.M., et al. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS 2006, 20:387-395.
80. Merriman R.B. Nonalcoholic fatty liver disease and HIV infection. Curr HIV/AIDS Rep 2006, 3:113-117.
81. Piroth L. Liver steatosis in HIV-infected patients. AIDS Rev 2005, 7:197-209.
82. Mallet V., Blanchard P., Verkarre V., et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007, 21:187-192.
83. Garvey L.J., Thomson E.C., Lloyd J., et al. Response to Mallet et al "Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients.". AIDS 2007, 21:1494-1495.
84. Yusuf T.E., Baron T.H. AIDS cholangiopathy. Curr Treat Options Gastroenterol 2004, 7:111-117.
85. Ko W.F., Cello J.P., Rogers S.J., et al. Prognostic factors for the survival of patients with AIDS cholangiopathy. Am J Gastroenterol 2003, 98:2176-2181.
86. Cello J.P. Acquired immunodeficiency syndrome cholangiopathy: spectrum of disease. Am J Med 1989, 86:539-546.
87. Nash J.A., Cohen S.A. Gallbladder and biliary tract disease in AIDS. Gastroenterol Clin North Am 1997, 26:323-335.
88. Keaveny A.P., Karasik M.S. Hepatobiliary and pancreatic infections in AIDS: part II. AIDS Patient Care STDS 1998, 12:451-456.
89. Klatt E.C., Nichols L., Noguchi T.T. Evolving trends revealed by autopsies of patients with the acquired immunodeficiency syndrome: 565 autopsies in adults with the acquired immunodeficiency syndrome, Los Angeles, Calif, 1982-1993 [corrected]. Arch Pathol Lab Med 1994, 118:884-890.
90. Bonacini M. Hepatobiliary complications in patients with human immunodeficiency virus infection. Am J Med 1992, 92:404-411.
91. Keaveny A.P., Karasik M.S. Hepatobiliary and pancreatic infections in AIDS: part one. AIDS Patient Care STDS 1998, 12:347-357.
92. Poles M.A., Lew E.A., Dieterich D.T. Diagnosis and treatment of hepatic disease in patients with HIV. Gastroenterol Clin North Am 1997, 26:291-321.
93. Chaisson R.E., Schecter G.F., Theuer C.P., et al. Tuberculosis in patients with the acquired immunodeficiency syndrome: clinical features, response to therapy, and survival. Am Rev Respir Dis 1987, 136:570-574.
94. Viriyavejakul P., Rojanasunan P., Viriyavejakul A., et al. Opportunistic infections in the liver of HIV-infected patients in Thailand: a necropsy study. Southeast Asian J Trop Med Public Health 2000, 31:663-667.
95. Huang C.T., McGarry T., Cooper S., et al. Disseminated histoplasmosis in the acquired immunodeficiency syndrome: report of five cases from a nonendemic area. Arch Intern Med 1987, 147:1181-1184.
96. Ng V.L., Yajko D.M., Hadley W.K. Extrapulmonary pneumocystosis. Clin Microbiol Rev 1997, 10:401-418.
97. Perkocha L.A., Geaghan S.M., Yen T.S., et al. Clinical and pathological features of bacillary peliosis hepatis in association with human immunodeficiency virus infection. N Engl J Med 1990, 323:1581-1586.
98. Hindupur S., Yeung M., Shroff P., et al. Vanishing bile duct syndrome in a patient with advanced AIDS. HIV Med 2007, 8:70-72.
99. Aldeen T., Davies S. Vanishing bile duct syndrome in a patient with advanced AIDS. HIV Med 2007, 8:573-574.